

M DCH A Quick Look at Using Rotavirus Vaccines: RV5 (RotaTeq®) and RV1 (ROTARIX®)

Indications for Use and Schedule

Two rotavirus vaccines are licensed. Both are live, attenuated vaccines.

	RV5 (RotaTeq®)	RV1 (ROTARIX®)
Number of doses in series	3	2
Recommended ages for doses	2, 4, and 6 months	2 and 4 months
Minimum age for first dose	6 weeks	
Maximum age for first dose	14 weeks, 6 days	
Minimum interval between doses	4 weeks	
Maximum age for last dose	8 months, 0 days	


- Complete the rotavirus series with the same product (RV5 or RV1) whenever possible
- Vaccination should not be deferred if the product used for previous doses is not available or unknown
- If any dose in the series was RV5 (RotaTeq) or the product is unknown for any dose in the series, a total of three doses should be given

Vaccine Administration

- RV5: Given orally, 2 mL (premixed)
- RV1: Given orally, 1 mL (need to reconstitute)
- Can be given with other vaccines, at the same visit
- Do not add to other liquids or food
- Do not repeat doses that are spit up or vomited; Count the dose and give the next dose as scheduled

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8°C)
- Do NOT freeze
- Keep in the original boxes
- Live vaccine vials, syringes, & tubes must be discarded into biologic waste containers



CONTRAINDICATIONS

- Previous anaphylactic reaction to a rotavirus vaccine or a component of the vaccine
- History of Severe Combined Immunodeficiency Disease (SCID)
- History of intussusception
- History of uncorrected congenital malformation of the gastrointestinal tract that predisposes the infant to intussusception (Rotarix)

PRECAUTIONS

- Moderate to severe illness or acute, moderate to severe gastroenteritis or vomiting
- Pre-existing chronic gastrointestinal disease
- History of receiving a blood transfusion or blood product, including immunoglobulins, within 42 days
- Altered immunocompetence such as: blood dyscrasias, leukemia, on immunosuppressive therapy (including high-dose systemic corticosteroids), primary and acquired immunodeficiency states, including HIV/AIDS, cellular immune deficiencies *and hypogammaglobulinemic and dysgammaglobulinemic states*
- Moms who are HIV/AIDS positive and the infant's HIV status is unknown

FURTHER POINTS

- Rotarix **must** be reconstituted using the applicator prefilled with diluent & transfer adapter supplied with the Rotavirus vaccine vial; RotaTeq vaccine is ready to use.
- Record the lot number and expiration date for Rotarix from the inside box that contains the vaccine vials (do not use the number from the outer box).
- Vaccines for Children (VFC) providers and VIM users will also need to enter into MCIR the NDC number from the inside box
- There is one combined Rotavirus Vaccine Information Statement (VIS). Use this copy or the Multi-vaccine VIS that includes information about the Michigan Care Improvement Registry (MCIR). VISs with MCIR information are available at www.michigan.gov/immunize or at your local health department.
- Document as "RV1 (Rotarix)" or "RV5 (RotaTeq)" in MCIR; document as RV1 or RV5 on the vaccine administration record & immunization record card
- Rotavirus vaccine may be used with premature infants (discharged from the hospital and clinically stable) or a child living with a pregnant woman or immunocompromised persons.

Publicly purchased RV5 and RV1 can be administered to eligible children 6 weeks to 8 months of age through the Vaccines for Children (VFC) Program in private providers' offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.

For additional information, refer to CDC/ACIP Recommendations on Rotavirus Vaccines including supplemental MMWR publications on intussusception and contraindications at <http://www.cdc.gov/vaccines/recs>